期刊文献+

人肝癌顺铂耐药细胞系SK-Hep1/CDDP的建立 被引量:9

Establishment of a cisplatin-induced multidrug resistance cell line SK-Hep1/DDP
下载PDF
导出
摘要 背景与目的:多药耐药是肿瘤治疗的主要障碍,本研究旨在建立人肝癌多药耐药细胞株SK-Hep1/CDDP,并对其生物学特性及发生多药耐药的可能机制进行初步评价。方法:采用大剂量冲击,间歇诱导法获得人肝癌顺铂(Cisplatin,CDDP)多药耐药系SK-Hep1/CDDP;CCK-8法检测药物敏感性,计算半数抑制浓度(IC50)和耐药指数(RI);Western blot检测多药耐药基因(MDR1,ABCB1)、多药耐药相关蛋白1(MRP-1,ABCC1)、多药耐药相关蛋白2(MRP-2,ABCC2)、Bax蛋白的表达,以及加入MDR1抑制剂CsA对肝癌细胞MDR1蛋白的表达影响;流式细胞仪(FCM)检测细胞周期及凋亡率。结果:历时6个月建成SK-Hep1/CDDP细胞株,其对CDDP的耐药指数为13.76,并对盐酸阿霉素(doxorubicin,DOX)、氟尿嘧啶(5-Fluororacil,5-FU)等多种抗肿瘤药物交叉耐药;Westernblot发现SK-Hep1/CDDP与亲本细胞相比MDR1、MRP-1、MRP-2的表达明显升高(P<0.01),Bax蛋白表达明显降低(P<0.01),加入小剂量环孢素A对肝癌细胞MDR1蛋白的表达无影响(P>0.05);细胞周期分析发现相对于亲本SK-Hep1细胞[G1期为(59.83±3.28)%,S期为(27.91±2.16)%,G2/M期为(12.14±3.36)%],SK-Hep1/CDDP耐药细胞[G1期为(37.50±5.05)%,S期为(42.20±2.65)%,G2/M期(20.67±5.69)%]的G2/M,S期比例增加,G1期比例减少,两组相比差异均有统计学意义(P<0.01);流式细胞仪分析表明CDDP对耐药细胞SK-Hep1/CDDP的凋亡率明显减少,加入MDR1抑制剂干预后可明显增加CDDP对SK-Hep1/CDDP细胞的凋亡率。结论:成功建立MDR细胞株SK-Hep1/CDDP,其耐药机制可能与MDR1、MRP-1、MRP-2蛋白的表达增加,Bax蛋白表达降低及降低化疗药物诱导肿瘤细胞的凋亡作用相关。 Background and Objective: Multidrug resistance (MDR) is a major obstacle in the chemotherapy of cancer patients. The aim of this study was to establish a mutidrug-resistant cell line SK-Hep1/DDP and explore its molecular mechanism of the MDR. Methods: SK-Hep1/DDP cell line was induced by pulse treatment using a high concentration of cisplatin (DDP) in vitro. The chemoresistance indexes of cells were evaluated by CCK-8 assays. The protein of MDR1 (ABCB1), MRP1 (ABCC1), MRP2 (ABCC2) and Bax were detected by Western blotting, and the effect of MDR1 inhibitor cyclosporine A (CsA) on expression of MDR1 proteins in SK-Hep1 and SK- Hep1/DDP cell lines. Flow cytometry was performed to determine the distribution of the cell cycle and cell apoptosis ratio. Results: The SK-Hep1/ DDP cells were 13.76 times more resistant to DDP in comparison with SK- Hep1 cells, and SK-Hep1/DDP cells also exhibited cross-resistance to many other chemotherapeutic agents (for example adramycin and 5-fuorouracil). MDR1, MRP1 and MRP2 protein expressions were significantly higher in the SK-Hepl/DDP than in the SK-Hep1 (P〈0.01), but Bax was lower in the SK- Hep1/DDP than in the SK-Hepl (P〈0.01). There was no obvious influence between SK-Hep1 and SK-Hep1/DDP cells in the expression of MDR1 by MDR1 inhibtor CsA (P〉 0.05). The percentages of cells in G2/M and S phase were significantly increased in SK-Hep1/DDP in comparison with those in SK-Hep1 [(20.67±5.69)% vs. (12.14 ± 3.36)% ; (42.20±2.65)% vs. (27.91 ± 2.16)%; P〈 0.01]. Afterthe cells were exposed to 10 μg/mL DDP for 24 h, the cell apoptosis rate of SK-Hep1/DDP was decreased in comparison with SK-Hep1, but it was increased in those with pretreatment of MDR1 inhibitor CsA as compared with those without pretreatment. Conclusions: A reliable multidrug-resistant human hepatoma cell line SK- Hep1/DDP is successfully established. The MDR mechanisms of this cell lines are closely related to the over-expression of MDR1, MRP1 and MRP2, lower expression of Bax, and the attenuated cell apoptosis induced by chemotherapeutic agents.
作者 周源 凌贤龙
出处 《癌症》 SCIE CAS CSCD 北大核心 2010年第2期176-181,共6页 Chinese Journal of Cancer
基金 第三军医大学附属新桥医院1520人才培养工程专项基金~~
关键词 肝肿瘤 顺铂 多药耐药 SK—Hep1细胞株 MDR1 MRP-1 MRP-2 Hepatoma, cisplatin, multidrug resistance, SK-Hep1 cell line,MDR1, MRP1, MRP2
  • 相关文献

参考文献11

  • 1Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment [J]. Curr Med Chem, 2006,13 (16) : 1859-1876.
  • 2Liu FS. Mechanisms of chemotherapeutic drug resistance in cancer therapy--a quick review [J]. Taiwan J Obstet Gynecol, 2009,48 (3) : 239-244.
  • 3Watson MB, Lind M J, Cawkwell L. Establishment of in-vitro models of chemotherapy resistance [J]. Anticancer Drugs, 2007,18(7):749-754.
  • 4Szakacs G, Paterson J, Ludwig J, et al. Targeting multidrug resistance in cancer [J]. Nat Rev Drug Discov, 2006,5(3): 219-234.
  • 5Teodori E, Dei S, Martelli C, et al. The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control muhidrug resistance (MDR) [J]. Curr Drug Targets, 2006,7(7):893-909.
  • 6Daood M, Tsai C, Ahdab-Barmada M, et al. ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS [J]. Neuropediatrics, 2008,39(4): 211-218.
  • 7Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy [J]. Oncogene, 2006,25 (34) :4798-4811.
  • 8Pommier Y, Sordet O, Antony S, et al. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks [ J ]. Oncogene, 2004,23 (16) : 2934-2949.
  • 9Bremer E, van Dam G, Kroesen BJ, et al. Targeted induction of apoptosis for cancer therapy: current progress and prospects[J]. Trends Mol Med, 2006,12(8):382-393.
  • 10Mor G, Montagna MK, Alvero AB. Modulation of apoptosis to reverse chemoresistance [J]. Methods Mol Biol, 2008,414(2): 1-12.

同被引文献90

引证文献9

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部